TY - JOUR
T1 - Gastrointestinal involvement in systemic sclerosis
T2 - pathogenesis, assessment and treatment
AU - Volkmann, Elizabeth R.
AU - McMahan, Zsuzsanna
N1 - Publisher Copyright:
© 2022 Lippincott Williams and Wilkins. All rights reserved.
PY - 2022/11/1
Y1 - 2022/11/1
N2 - Purpose of reviewThe majority of patients with systemic sclerosis (SSc) will experience involvement of their gastrointestinal over the course of their disease. Despite the high prevalence of gastrointestinal involvement in SSc, the strategies pertaining to the assessment and treatment for this clinical dimension of SSc have historically been limited. However, the present review highlights recent research contributions that enhance our understanding of SSc-GI patient subsets and provides updates on pathogenic mechanisms of disease, assessment and symptom-directed management.Recent findingsIn the past few years, several studies have identified risk factors for more severe gastrointestinal disease in SSc and have provided insight to optimize diagnosis and management of SSc-GI symptoms. This article also provides a review of currently available investigations and therapies for individual SSc-GI disease manifestations and reflects on actively evolving areas of research, including our understanding the role of the gut microbiome in SSc.SummaryHere, we provide important updates pertaining to the risk stratification, assessment, diagnosis and management of SSc patients with gastrointestinal symptoms. These findings provide opportunities to enhance patient care and highlight exciting opportunities for future research.
AB - Purpose of reviewThe majority of patients with systemic sclerosis (SSc) will experience involvement of their gastrointestinal over the course of their disease. Despite the high prevalence of gastrointestinal involvement in SSc, the strategies pertaining to the assessment and treatment for this clinical dimension of SSc have historically been limited. However, the present review highlights recent research contributions that enhance our understanding of SSc-GI patient subsets and provides updates on pathogenic mechanisms of disease, assessment and symptom-directed management.Recent findingsIn the past few years, several studies have identified risk factors for more severe gastrointestinal disease in SSc and have provided insight to optimize diagnosis and management of SSc-GI symptoms. This article also provides a review of currently available investigations and therapies for individual SSc-GI disease manifestations and reflects on actively evolving areas of research, including our understanding the role of the gut microbiome in SSc.SummaryHere, we provide important updates pertaining to the risk stratification, assessment, diagnosis and management of SSc patients with gastrointestinal symptoms. These findings provide opportunities to enhance patient care and highlight exciting opportunities for future research.
KW - gastrointestinal tract
KW - microbiome
KW - motility
KW - scleroderma
KW - systemic sclerosis
UR - http://www.scopus.com/inward/record.url?scp=85139572895&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85139572895&partnerID=8YFLogxK
U2 - 10.1097/BOR.0000000000000899
DO - 10.1097/BOR.0000000000000899
M3 - Review article
C2 - 35993874
AN - SCOPUS:85139572895
SN - 1040-8711
VL - 34
SP - 328
EP - 336
JO - Current opinion in rheumatology
JF - Current opinion in rheumatology
IS - 6
ER -